OXGENE, a leader in synthetic biology, is a specialised contract research organisation offering services to support the discovery, development and production of biologics, gene and cell therapies. A unifying theme across the portfolio is expertise in designing DNA, optimising expression of proteins, cell line development, and improving viral delivery systems. OXGENE is headquartered in Oxford, UK.
Location: United Kingdom, England, Oxford
Employees: 51-200
Phone: +44 1865 415107
Total raised: $1.23M
Founded date: 2011
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.05.2020 | - | $1.23M | Mercia Ass... |
Mentions in press and media 4
| Date | Title | Description |
| 21.10.2021 | Mercia Asset Management : Spotlight on our EIS Funds – Dr Paul Mattick | It has been a very successful year for Mercia's Enterprise Investment Scheme ("EIS") portfolio, particularly in the Life Sciences and Software sectors. Importantly, existing clients are pleased with the performance of Mercia's EIS... |
| 21.10.2021 | Spotlight on our EIS Funds – Dr Paul Mattick | It has been a very successful year for Mercia’s Enterprise Investment Scheme (“EIS”) portfolio, particularly in the Life Sciences and Software sectors. Importantly, existing clients are pleased with the performance of Mercia’s EIS funds, an... |
| 10.05.2021 | Julian Viggars, CIO: Realising value: six exits mark a successful year | Mercia has solidified its position as one of the country’s leading regional investors able to drive significant and profitable realisations through its Complete Connected Capital model. Julian Viggars, Mercia’s CIO, provides an overview of ... |
| 06.05.2020 | Mercia invests £1.0million into OXGENE™ | OXGENE™ combines precision engineering, biology, robotics and bioinformatics to accelerate the design, discovery and manufacture of new biologics. Working across the fields of gene therapy, gene editing and antibody therapeutics, OXGENE™ ha... |